PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were payer and industry stakeholders in both Europe and Canada.
The current issue presents the perspectives of stakeholders on the biosimilar market. Recent experience in Norway suggests that significant price discounting may be a key factor in overcoming resistance to reimbursing a biosimilar over a brand biologic. Australia is also considering new pathways for biosimilar uptake. With the introduction of Inflectra™ (infliximab), a biosimilar of Remicade™, into the Canadian market, many important questions are being raised on substitution and extrapolation of indication as such products make their way through the reimbursement channels.
This paper presents the opinions of stakeholders on the practice of substitutability and extrapolation of indications along with some Canadian public claims data for Inflectra™ vs. Remicade™ in Quebec. Please click here a complimentary copy of the fourth issue, “Uptake of Biosimilars.”
Over the coming weeks, we will be releasing a series of papers focusing on the following issues about which participants were asked to share their insights:
- Delisting of Oncology Treatments
- Off-Label Prescribing Provisions
- Downgrading of Benefits
- Uptake of Biosimilars
- Private Payer Exclusivity Agreements
If you have any questions regarding the paper, please contact Courtney Abunassar, PDCI’s Manager of Market Access and Policy Research.